An inhibitor of microtubule assembly
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Vinblastine (sulfate)

Item No. 11762

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
vincaleukoblastine, monosulfate
CAS Number
143-67-9
Synonyms
  • 29060LE
  • Alkaban-AQ
  • Exal
  • NSC 49842
  • Rozevinsulfate
  • Velban®
  • Velsar
  • Vincaleukoblastinesulfate
  • VLB
Molecular Formula
C46H58N4O9 • H2SO4
Formula Weight
909.1
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 16 mg/mlDMSO: 10 mg/mlPBS (pH 7.2): 0.5 mg/ml
λmax
215, 267 nm
SMILES
CC[C@]1(O)C[C@@](C[N@@](CC2)C1)([H])C[C@](C(OC)=O)(C3=C(OC)C=C(N(C)[C@]4([H])[C@@]56[C@](N7CC6)([H])[C@](C=CC7)(CC)[C@@H](OC(C)=O)[C@]4(O)C(OC)=O)C5=C3)C8=C2C(C=CC=C9)=C9N8.O=S(O)(O)=O
InChi Code
InChI=1S/C46H58N4O9.H2O4S/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7;1-5(2,3)4/h10-14,16,21-22,28
InChi Key
KDQAABAKXDWYSZ-PNYVAJAMSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $63

    Add

    10 mg

    $98

    Add

    25 mg

    $197

    Add

    50 mg

    $363

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Vinblastine, derived from C. roseus, also known as V. rosea, a Madagascar periwinkle, is an antimicrotubule drug used to treat certain cancers, including Hodgkin’s lymphoma, non-small cell lung, breast, head and neck, and testicular cancer. Like its chemical analog vincristine, vinblastine binds tubulin, inhibiting the assembly of microtubules and causing M phase-specific cell cycle arrest by disrupting microtubule assembly and proper formation of the mitotic spindle. It has been shown to inhibit steady-state tubulin addition to microtubules with a Ki value of 0.18 μM, inhibit B16 melanoma cell proliferation with an IC50 value of 1 nM, and produce complete inhibition of L-cell proliferation at 40 nM.1 Vinblastine is reported to be an effective component of certain chemotherapy regimens, particularly when used with bleomycin and methotrexate in vinblastine, bleomycin, and methotrexate combination chemotherapy for Stage IA or IIA Hodgkin lymphomas.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Jordan, M.A., Himes, R.H., and Wilson, L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 45(6), 2741-2747 (1985).

    2. Martinelli, G., Cocorocchio, E., Saletti, P.C., et al. Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients. Leuk. Lymphoma 44(11), 1919-1923 (2003).

    Product Citations

    Huang, J.J., Corona, A.L., Dunn, B.P., et al. Increased type III TGF-β receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition. Oncogene 38(18), 3402-3414 (2019).